Longeveron LGVN 深 沪
等待开盘 05-19 09:30:00 美东时间
0.6761
+0.006
+0.84%
华盛通- 最 高0.6761
- 今 开0.66
- 成交量 39.32万股
- 最 低 0.65
- 昨 收 0.6705
- 总市值 2105.80万
- 52周最高 1.80
- 市盈率 静 --
- 换手率 1.26%
- 52周最低 0.475
- 委 比 -85.74%
- 总股本 3114.63万
- 历史最高 450.00
- 量 比 0.61
- 振 幅 3.89%
- 历史最低 0.475
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ Longeveron(LGVN)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Longeveron业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度总营收40万美元，与2025年同期持平。其中临床试验收入40万美元，合同制造收入2万美元。 **亏损情况：** 净亏损470万美元，较2025年同期的500万美元减少30万美元。 **费用控制：** 一般管理费用270万美元，研发费用230万美元，两项费用均实现同比下降。 **现金状况：** 截至2026年3月31日，现金及现金等价物余额1,580万美元。 ## 2. 财务指标变化 **营收结构变化：** - 临床试验收入同比增长
05-14 12:24
Longeveron Q1 2026 Earnings Call: Complete Transcript
On Wednesday, Longeveron (NASDAQ:LGVN) discussed first-quarter financial result...
05-14 05:09
Longeveron Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $398.000K Beat $314.667K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 44.12 percent increase over losses of $(0.34) per share from the
05-14 04:42
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Maxim Group Downgrades Longeveron to Hold
Maxim Group analyst Michael Okunewitch downgrades Longeveron (NASDAQ:LGVN) from Buy to Hold.
05-12 03:42
Longeveron Phase 2b HLHS Cell Therapy Trial Clears Final Safety Review; Top-Line Results Expected August 2026
Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationDMC performed a risk-benefit assessment, identified no new
05-11 21:11
Longeveron Updates FDA Path for ELPIS II Trial
An update from Longeveron ( ($LGVN) ) is now available. On May 8, 2026, Longeve...
05-09 05:24
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
HC Wainwright & Co. Maintains Buy on Longeveron, Lowers Price Target to $8
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target from $10 to $8.
05-04 19:49
Longeveron Restores Executive Pay After Recent Financing
The latest announcement is out from Longeveron ( ($LGVN) ). In February 2026, L...
04-11 05:33
